Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 29, 2025
Business Overview: Henry Schein is a global solutions company for healthcare professionals, primarily serving office-based dental and medical practitioners. The company operates through three reportable segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $3,168 | $3,172 |
| Gross Profit | $1,000 | $1,012 |
| Gross Margin | 31.6% | 31.9% |
| Operating Income | $175 | $150 |
| Net Income (Total) | $113 | $98 |
| Net Income Attributable to Henry Schein | $110 | $93 |
| Diluted EPS | $0.88 | $0.72 |
| Operating Cash Flow | $37 | $197 |
| Total Debt | $2,891 | $2,536 |
| Cash and Cash Equivalents | $127 | $159 |
Material Changes vs. Prior Period
- Revenue: Net sales decreased slightly by 0.1% ($4 million) to $3,168 million. This was driven by a 1.5% negative impact from foreign exchange, partially offset by 1.2% growth from acquisitions and 0.2% internal local currency growth.
- Profitability: Operating income increased 16.7% to $175 million, and Net Income attributable to Henry Schein increased 18.3% to $110 million. This improvement occurred despite a slight decline in gross margin, primarily due to lower operating expenses (excluding adjustments) and a favorable impact from cyber incident insurance proceeds.
- Cash Flow: Net cash provided by operating activities decreased significantly by $160 million to $37 million. This decline is attributed to changes in working capital accounts (specifically accounts receivable, inventory, and payables) and the normalization of cash collections following the residual impacts of the 2023 cyber incident in the prior year.
- Debt: Total debt increased by $355 million to $2,891 million, driven by increased borrowings to finance investments and acquisitions.
Guidance, Outlook, and Material Events
- Cyber Incident Resolution: The company received the remaining $20 million in insurance proceeds related to the October 2023 cyber incident during Q1 2025. No direct expenses related to the incident were incurred in the current quarter.
- Restructuring: The company recorded $25 million in restructuring charges under the "2024 Plan," primarily for severance and employee-related costs. The company expects to continue recording charges through the end of 2025, though a total estimate has not been determined.
- Strategic Investment: In January 2025, Henry Schein announced a strategic investment by KKR. KKR will invest an additional $250 million in common stock, resulting in an approximate 12% ownership stake. Two independent directors will join the Board.
- Share Repurchases: The Board authorized an additional $500 million for share repurchases in January 2025. During Q1 2025, the company repurchased approximately 2.26 million shares for $162 million. Approximately $718 million remains available under the program.
- Legal Proceedings: The company is a defendant in multiple opioid-related lawsuits. A class action filed by San Miguel Hospital Corporation was dismissed with prejudice in March 2025. A trial involving Florida Health Sciences Center is scheduled for September 2025.
- Tariffs: New U.S. tariffs on imports did not have a material impact on Q1 2025 results, though the environment remains volatile.
Investor Verification Checklist
- Working Capital Trends: Verify the sustainability of the $160 million drop in operating cash flow and monitor accounts receivable days sales outstanding (44.1 days) and inventory turns (4.8) for signs of normalization or strain.
- Restructuring Costs: Monitor future quarters for the total cost of the 2024 restructuring plan, as the final estimate is currently undetermined.
- KKR Investment Impact: Assess the long-term strategic implications of the KKR investment and the addition of new board members on corporate governance and strategy.
- Opioid Litigation: Track the status of the September 2025 trial and potential settlement outcomes, noting that opioid sales represent less than 0.4% of total net sales.
- Debt Levels: Review the increase in total debt to $2.89 billion and the company's leverage ratios in light of increased borrowing for acquisitions and share buybacks.